Items Tagged ‘Renal Cancer’

May 24th, 2016

Lenvima® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic agent, and is to be used in combination with the standard agent Afinitor® (everolimus). Each year […]

View full entry

Tags: afinitor, everolimus, fda, General Renal Cancer, kidney cancer, lenvatinib, Lenvima, News, rcc, Renal Cancer, RTK


May 10th, 2016

Cabometyx® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed […]

View full entry

Tags: Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, kinase inhibitor, metastatic, News, rcc, Renal Cancer, renal cell carcinoma


March 15th, 2016

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

By

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC. The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is […]

View full entry

Tags: axitinib, clinical trial, dalantercept, DART study, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, renal cell carcinoma, study


November 25th, 2015

FDA Approves Opdivo for Renal Cell Carcinoma

By

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung cancer. About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell cancer


October 15th, 2015

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

By

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared to Afinitor® (everolimus) in patients with advanced kidney cancer whose cancer has progressed following VEGRF-targeted therapy. Each year in the United States, more than 58,000 people are […]

View full entry

Tags: afinitor, cabozantinib, COMETRIQ, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, VEGFR-targeted agents


October 12th, 2015

Opdivo® Improves Survival in Kidney Cancer

By

The immunotherapy agent, Opdivo® (nivolumab), improves survival in kidney cancer compared to the standard treatment, Afinitor® (everolimus). These results were recently published in the New England Journal of Medicine. About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are diagnosed with kidney cancer. The most common type of kidney cancer […]

View full entry

Tags: afinitor, kidney cancer, metastatic, News, opdivo, rcc, Renal Cancer, renal cell carcinoma


July 29th, 2015

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival

By

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase III clinical trial. Because the improved survival with Opdivo was apparent sooner than expected, the trial has been stopped early. Each year in the United States, […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell carcinoma


June 9th, 2014

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers

By

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American Society of Clinical Oncology® (ASCO®) Annual […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, General Renal Cancer, genomic testing, kidney cancer, News, oncotype, Prostate Cancer, Renal Cancer


September 16th, 2013

End-of-Life Care Remains Aggressive, Despite Patient Wishes

By

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive intensive treatment until the last month of life and hospice care is often delayed until the final three […]

View full entry

Tags: All Cancer Types, Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, HIV Related Cancers


May 15th, 2013

Following Lifestyle Recommendations Reduces Risk of Cancer Death

By

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent reduced risk of dying from cancer compared to people who don’t follow the recommendations, […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General, Head and Neck Cancer, HIV Related Cancers


February 11th, 2013

Cancer Deaths on the Decline

By

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence rates for both sexes combined decreased by 1.5 percent per year from 2000 to 2009 and […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General, Head and Neck Cancer, HIV Related Cancers


October 8th, 2012

New Treatment Options for Advanced Renal Cell Carcinoma

By

The results from three phase III trials shed new light on treatment options for patients with advanced renal cell carcinoma. The studies were presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. More than 58,000 people are diagnosed with kidney cancer in the United States each year. The most […]

View full entry

Tags: General Renal Cancer, News, Renal Cancer


June 11th, 2012

PD-1 Targeted Immune Therapy Shows Promising Activity

By

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase I study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. BMS-936558 is a targeted immune […]

View full entry

Tags: General Renal Cancer, Lung Cancer - Non-Small Cell, Melanoma, News, Recurrent Lung Cancer - Non-Small Cell, Recurrent Melanoma, Renal Cancer, Stage IV Melanoma, Urology


May 17th, 2012

Approximately 16% of Worldwide Cancers Caused By Preventable Infections

By

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet Oncology.[1] Infections with certain viruses, bacteria, and parasites have been identified as strong risk factors for […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, HIV Related Cancers, Hodgkin's Lymphoma


April 27th, 2012

Partial Nephrectomy is Associated with Improved Survival in Early Stage Kidney Cancer

By

Patients with early stage kidney cancer who had only the tumor removed experienced better survival rates than those who had the entire kidney removed, according to the results of a study published in the Journal of the American Medical Association.[1] Nearly 65,000 people are diagnosed with kidney cancer in the United States each year. For […]

View full entry

Tags: General Renal Cancer, News, Renal Cancer, Urology